IL-1-Targeted Therapy in Dermatologic Conditions
Listen to this summary
The authors investigate the efficacy of IL-1-targeted therapies in various dermatologic conditions, particularly those characterized by neutrophil-rich inflammation. They find strong evidence supporting the use of IL-1 blockade in specific syndromes like cryopyrin-associated periodic syndromes and Schnitzler syndrome, while noting variable responses in other conditions. The paper emphasizes the need for careful clinical and genetic assessment to optimize treatment outcomes with IL-1 antagonists.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.
More in Dermatology
View all →Jun 24, 2026 · The New England journal of medicine
Prevention and Treatment of Peanut Allergy
Jun 24, 2026 · Lancet (London, England)
Efficacy and safety of tirofiban after successful endovascular reperfusion in acute ischaemic stroke (ATTRACTION) in China: a multicentre, double-blind, randomised controlled trial
Jun 24, 2026 · Lancet (London, England)
Safety, pharmacokinetics, and exploratory efficacy of the oral ghrelin receptor agonist AC01 in heart failure with reduced ejection fraction (GOAL-HF1): a randomised, double-blind, placebo-controlled, phase 1b/2a study
Jun 24, 2026 · The New England journal of medicine
A Pragmatic Trial of a 6-Month Strategy for Rifampicin-Resistant Tuberculosis
Jun 24, 2026 · The New England journal of medicine
Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas
Jun 23, 2026 · Lancet (London, England)
Non-invasive removal of the Smart tracheal occlusion device for fetal congenital diaphragmatic hernia: a single-arm, open-label, phase 1 study
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR
Stay current without falling behind
33,000+ journals. 3-minute audio summaries. Free for 14 days.
